Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Return on Invested Capital (2016 - 2025)

Historic Return on Invested Capital for Ligand Pharmaceuticals (LGND) over the last 15 years, with Q3 2025 value amounting to 0.02%.

  • Ligand Pharmaceuticals' Return on Invested Capital rose 300.0% to 0.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.02%, marking a year-over-year increase of 300.0%. This contributed to the annual value of 0.05% for FY2024, which is 300.0% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Return on Invested Capital of 0.02% as of Q3 2025, which was up 300.0% from 0.04% recorded in Q2 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Return on Invested Capital peaked at 0.14% during Q2 2021, and registered a low of 0.06% during Q1 2025.
  • Its 5-year average for Return on Invested Capital is 0.03%, with a median of 0.01% in 2023.
  • Within the past 5 years, the most significant YoY rise in Ligand Pharmaceuticals' Return on Invested Capital was 1500bps (2021), while the steepest drop was -2300bps (2021).
  • Ligand Pharmaceuticals' Return on Invested Capital (Quarter) stood at 0.13% in 2021, then tumbled by -100bps to 0.0% in 2022, then skyrocketed by 2598bps to 0.01% in 2023, then skyrocketed by 194bps to 0.04% in 2024, then plummeted by -65bps to 0.02% in 2025.
  • Its Return on Invested Capital stands at 0.02% for Q3 2025, versus 0.04% for Q2 2025 and 0.06% for Q1 2025.